"We are pleased and proud to announce the results of our TK 210 ELISA test in this breast cancer study" states Jan Stålemark, AroCell CEO. "Furthermore, this study established that combinational approach of TK 210 ELISA test with CA 15-3 significantly increased the diagnostic sensitivity. These fundamental results are proof that our CE-marked TK 210 ELISA test works in clinical application and can provide important information to oncologists during the course of treatment. These results are important for the continued clinical validation of our test to achieve broad clinical acceptance".
Link to the full article published online 14 April 2016: https://arocell.com/research-references/list-of-publications-2/
For further information:
Jan Stålemark, CEO
AroCell AB (pub)
Pho: +46-706 926 206
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell is listed at AktieTorget (AROC) and has about 2 800 shareholders.